Xeris Biopharma Holdings Inc. Stock
A very strong showing by Xeris Biopharma Holdings Inc. today, with an increase of €0.28 (4.420%) compared to yesterday's price.
Xeris Biopharma Holdings Inc. is currently one of the favorites of our community with 8 Buy predictions and no Sell predictions.
With a target price of 8 € there is a slightly positive potential of 16.86% for Xeris Biopharma Holdings Inc. compared to the current price of 6.85 €.
Pros and Cons of Xeris Biopharma Holdings Inc. in the next few years
Pros
?
C******** o* t** e**********
?
M***** P*******
?
S********** s********
Cons
?
B****
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Xeris Biopharma Holdings Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Xeris Biopharma Holdings Inc. | 4.420% | -6.193% | -9.300% | 16.528% | 8.409% | 216.944% | 233.951% |
| Heron Therapeutics Inc. | -5.660% | -35.714% | -23.680% | -74.673% | -74.309% | -81.771% | -97.186% |
| Evolus Inc | -0.740% | 23.433% | 12.001% | 29.160% | 18.495% | -25.770% | -32.021% |
| Rhythm Pharmaceuticals | -1.010% | 10.615% | 4.211% | 28.571% | 5.882% | 341.964% | 768.421% |
Comments
Xeris Biopharma (XERS) had its "buy" rating reaffirmed by HC Wainwright. They now have a $10.00 price target on the stock.
Show more
Ratings data for XERS provided by MarketBeat
Xeris Biopharma (NASDAQ:XERS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Show more
Ratings data for XERS provided by MarketBeat
Xeris Biopharma (NASDAQ:XERS) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
Show more
Ratings data for XERS provided by MarketBeat